OG DNA Genetics has signed a licensing agreement with UNIVO Pharmaceuticals LTD (“UNIVO”), an Israeli-based medical cannabis company.
This Agreement will grant UNIVO license to the DNA brand and access to their proprietary library of genetics for use at the company’s 5-acre cultivation facility located in the south of Israel.
“We’re excited to announce our partnership with UNIVO Pharmaceuticals and our entry into the rapidly developing Israeli medical cannabis market. Through this partnership, we will be able to bring our unique varieties to Israel and develop new and exciting cannabis-derived medicinal products to export internationally. We couldn’t ask for a better partner to enter the Israeli medical cannabis market with than UNIVO Pharmaceuticals,” said Rezwan Khan, President of DNA Genetics.
“We are pleased to announce a strategic joint venture with DNA Genetics, a well-known global player in the field of cannabis, who has examined the Israeli market and partnered with us to build a joint international brand. We strongly believe that the technological and marketing capabilities of both companies will result in a high quality and competitive brand that will be launched shortly, which will contribute to our market presence both locally and outside our domestic Israeli market,” said Golan Bitton, CEO of UNIVO Pharmaceuticals.
"We are pleased to partner with DNA Genetics, one of the leading companies in the field of cannabis genetics and farming. Our professional teams will collaborate on Amit Farm to develop new cannabis strains while growing the best genetics and make available the best products using our leading global standard farming infrastructure for the benefit of patients in Israel and other countries," said Omer Layani, Amit Farm Manager.